King cuts 20% of workforce

Tennessee-based King Pharmaceuticals said it will cut its workforce by 20 percent due to problems the company is having with its Altace franchise. Last month King Pharmaceuticals lost its fight with Indian generics maker Lupin when a federal appeals court invalidated the patent on Altace, a drug for high blood pressure. The company is also speeding up plans to focus its business on neuroscience and hospital/acute. The cuts will save the company between $75 million and $90 million in 2008.

- see King's release

Related Articles:
King regroups after patent fight loss. Report
King bails on Palatin's FSM program. Report
FDA rejects King's Altace. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.